Stay updated on ISB 830 Efficacy in Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the ISB 830 Efficacy in Atopic Dermatitis Clinical Trial page.

Latest updates to the ISB 830 Efficacy in Atopic Dermatitis Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page updates the display of the location region name to an English version (“Hradec Králové Region” instead of the Czech-language name) for the Náchod site. It also updates the site revision label from “Revision: v3.5.0” to “Revision: v3.5.3” without changing study details.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check48 days agoChange DetectedPage revision updated from v3.4.3 to v3.5.0, updating the version label on the study page.SummaryDifference0.0%

- Check62 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3. No changes to study content, sections, or navigation were introduced.SummaryDifference0.0%

- Check84 days agoChange DetectedMinor site version update from v3.4.1 to v3.4.2; no visible changes to core study content or user-facing features on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check92 days agoChange DetectedRevision label updated from v3.4.0 to v3.4.1 on the study page, indicating a minor update; no study data, endpoints, or eligibility criteria appear to be affected; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check113 days agoChange DetectedRevision: v3.3.4 is now shown in the revision history, replacing v3.3.3; no substantive study content or criteria were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to ISB 830 Efficacy in Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ISB 830 Efficacy in Atopic Dermatitis Clinical Trial page.